

March 25, 2025

For Immediate Release:

MTI Ltd.
Representative: Toshihiro Maeta,
President and Chief Executive Officer
Listing: TSE Prime [9438]
Contact: Hiroshi Matsumoto,
Senior Managing Director
Tel: +81-3-5333-6323

**Notice Regarding Acquisition of Shares in corte Inc. by Consolidated Subsidiary
Solamichi System Inc.**

Solamichi System Inc. (hereinafter "Solamichi System"), a consolidated subsidiary of our company, resolved at its Board of Directors meeting held on March 25, 2025, to subscribe to a third-party allotment of shares conducted by corte Inc. (hereinafter "corte"), a company that provides AI-powered medication history support services. Accordingly, we hereby announce the following. As a result of this transaction, Solamichi System's ownership ratio in corte will be 20.00%.

1. Reason for acquisition of shares

Corte has jointly developed the medication history entry support tool "corte" with Solamichi System. This tool uses generative AI to automatically summarize and display in text the conversations between pharmacists and patients during medication guidance in dispensing pharmacies. corte provides an AI-powered medication history support service using this tool.

The cloud-based medication history service "*CARADA Electronic Medication History Solamichi*", provided by Solamichi System, has incorporated "corte" as a built-in feature. This integration aims to improve pharmacists' operational efficiency by reducing the time required to create medication records, while also supporting the enhancement of medication guidance quality. As a result, business collaboration between Solamichi System and corte is steadily expanding.

Solamichi System has decided to subscribe to a third-party allotment of shares to be issued by corte in order to further strengthen its business collaboration with the company through a capital alliance.

*"corte" is a registered trademark of corte, Inc. (patent pending).

2. Overview of corte, Inc. (As of December 31, 2024)

(1) Name	corte, Inc.
(2) Address	1-13-5 Asakusa, Taito-ku, Tokyo
(3) Name and title of representative	Yusuke Masuzawa, CEO
(4) Nature of business	AI-powered medication history support service
(5) Capital stock	15 millions of yen
(6) Date of establishment	August 4, 2023

(7) Major shareholder and shareholding ratios	Individual 42.50% (*), Individual 30.00% (*), Yusuke Masuzawa 8.33%	
(8) Relationship between the listed company and the relevant company	Capital relationship	No capital relationship to be noted.
	Personal relationship	No personal relationship to be noted.
	Business relationship	No business relationship to be noted.

(*) The names of the individual shareholders who have become major shareholders will not be disclosed.

(Note) Corte's operating results and financial condition for the last three years are not disclosed because the company is unlisted and was established in August 2023.

3. Outline of the company acquiring the shares

(1) Name	Solamichi System Inc.
(2) Address	3-20-2, Nishi-Shinjuku, Shinjuku-ku, Tokyo
(3) Name and title of representative	Takahiro Taura, CEO
(4) Nature of business	Planning, development and sales of dispensing pharmacy internal systems
(5) Capital stock	100 millions of yen
(6) Date of establishment	August 21, 2018
(7) Major shareholder and shareholding ratios	MTI Healthcare Holdings Inc. 100%

4. Shares acquired and shares held

(1) Number of shares held before transfer	0 share
(2) Number of shares acquired	150 shares
(3) Number of shares held after transfer	150 shares (Number of voting rights: 150, Percentage of voting rights held: 20.00%)

(Note) The acquisition price will be undisclosed based on the results of discussions with corte.

5. Schedule

Date of Board of Directors' resolution (Solamichi System)	March 25, 2025
Date of payment for third-party allotment	March 31, 2025 (Scheduled)

6. Outlook for the future

The impact of this matter on our performance for the fiscal year ending September 2025 is expected to be minimal. However, if any matters requiring disclosure arise in the future, we will be announced promptly.

(Reference) Consolidated earnings forecast for the current fiscal year (announced on January 31, 2025) and consolidated results for the previous fiscal year

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Net income Per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Earnings forecast for FY2025 (For the fiscal year ending September 30, 2025)	28,500	2,800 ~3,200	2,900 ~3,300	2,050 ~2,330	37.20 ~42.28
FY2024 (Actual) (For the fiscal year ended September 30, 2024)	27,669	2,394	2,827	2,363	43.05

<Points to consider concerning forecasts>

Matters stated in this material concerning results forecasts are based on assessments, assumptions and convictions derived from information available to the Company at the time when this material is published. They may differ significantly from actual results due to a variety of factors, including future economic conditions in Japan and overseas, changes in conditions for business operations in Japan and overseas, or uncertain factors and potential risks inherent in forecasts. Those risks and uncertain factors include unpredictable effects on results that may arise from future events.

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

Contact information for inquiries

Investor Relations Office

E-mail: ir@mti.co.jp URL: <https://ir.mti.co.jp/eng/>